News
OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy Programme
New client programme to be supported from OXB’s FDA-approved, commercial scale viral vector manufacturing facility in Durham, North Carolina, underscoring increasing global demand for OXB’s end-to-end viral vector manufacturing capabilities Partnership further demonstrates momentum across OXB’s AAV business and ongoing……
View details >OXB Capital Markets Event
OXB to demonstrate how its global, multi-vector CDMO platform is positioned to capture growth in the cell and gene therapy market Event to highlight OXB’s proven track record, leading technical capabilities, expanded international manufacturing network, deep regulatory expertise and strong……
View details >OXB to exhibit and present at the 30th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Oxford, UK – 08 May 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 30th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place……
View details >OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture
New expedited service line designed for biotechs with timeline constraints, launched in response to client demand Can accelerate timeline to GMP manufacturing by up to nine months, driven by key innovations and efficiencies across upstream and downstream processes Oxford, UK……
View details >OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards
Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the CDMO Leadership Awards……
View details >Preliminary results for the year ended 31 December 2025
A year of strategic execution, strong revenue growth and positive Operating EBITDA Strong 2025 financial performance; revenues at upper end of guidance, with full year Operating EBITDA profitability achieved: Revenue growth of 33% to £170.9 million (CC) (FY 2024: £128.8……
View details >OXB enters into licensing agreement with Viral Vector Manufacturing Facility (VVMF), providing access to its AAV and LV viral vector platforms
Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into……
View details >OXB announces date for Capital Markets Day and participation in upcoming investor conferences
Oxford, UK – 3 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces the date of its Capital Markets Day and participation at upcoming investor conferences. Capital Markets Day OXB will hold……
View details >Full year Trading Update and Notice of Results
Revenues at the upper end of guidance and pivot to EBITDA profitability – expectations for 2026 unchanged and guidance reiterated Revenues expected to increase c.30% as OXB continues to execute its strategy, FY 2025 revenues expected to be £166-169……
View details >
